Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 7/20 | 0.76 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.76 |
| ▸ | GPBAR1 | Q8TDU6 | 8/20 | 0.61 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.56 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10547998 | 0.86 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2GPBAR1PDE10AFFAR1 | |
| SCHEMBL9844652 | 0.83 | CYSLTR1 (0.69) | CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL8636013 | 0.83 | PDE10A (0.63) | CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL6583310 | 0.82 | CYSLTR1 (0.78) | CYSLTR1CYSLTR2GPBAR1PDE10AFFAR1 | |
| SCHEMBL10607508 | 0.81 | CYSLTR1 (0.71) | CYSLTR1CYSLTR2GPBAR1PDE10AFFAR1 | |
| SCHEMBL10607417 | 0.81 | CYSLTR1 (0.66) | CYSLTR1CYSLTR2GPBAR1PDE10AFFAR1 | |
| SCHEMBL4159309 | 0.81 | CYSLTR1 (0.76) | CYSLTR1CYSLTR2GPBAR1PDE10AFFAR1 | |
| SCHEMBL10690965 | 0.81 | CYSLTR1 (0.76) | CYSLTR1CYSLTR2GPBAR1PDE10AFFAR1 | |
| SCHEMBL10547475 | 0.81 | CYSLTR1 (0.76) | CYSLTR1CYSLTR2GPBAR1PDE10AFFAR1 | |
| SCHEMBL7715797 | 0.81 | CYSLTR1 (0.76) | CYSLTR1CYSLTR2GPBAR1PDE10AFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741887-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-06-03 | — | — | US | claimed |
| EP-2621278-A1 | ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2013-08-07 | — | — | EP | claimed |
| US-8476302-B2 | α-ketoamide derivatives useful endothelial lipase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-07-02 | — | — | US | claimed |
| US-20130123232-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2013-05-16 | — | — | US | claimed |
| US-8367653-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-05 | — | — | US | claimed |
| US-8362000-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-29 | — | — | US | claimed |
| CN-102548982-A | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV | 2012-07-04 | — | — | CN | claimed |
| CN-102459230-A | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV | 2012-05-16 | — | — | CN | claimed |
| WO-2012047580-A1 | ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-12 | — | — | WO | claimed |
| US-20120077847-A1 | ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-29 | — | — | US | claimed |
| US-6608104-B2 | Antiarthritic agents; anticancer agents | PFIZER INC | 2003-08-19 | — | — | US | claimed |
| EP-0862557-B1 | SYMMETRICAL bis-HETEROARYLMETHOXYPHENYLALKYL CARBOXYLATES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | ABBOTT LAB (US) | 2002-11-27 | — | — | EP | claimed |
| US-20020019534-A1 | Gem substituted hydroxamic acids | PFIZER INC. | 2002-02-14 | — | — | US | claimed |
| US-5843958-A | Arylpyrazoles as leukotriene inhibitors | ORTHO PHARMACEUTICAL CORPORATION (US) | 1998-12-01 | — | — | US | claimed |
| EP-0667850-B1 | TARTRONIC ACIDS, THEIR ACETALIC ETHERS AND O-ESTERS | DOMPE FARMACEUTICI SPA (IT) | 1997-05-28 | — | — | EP | claimed |
| EP-0667850-A1 | TARTRONIC ACIDS, THEIR ACETALIC ETHERS AND O-ESTERS. | DOMPE FARMACEUTICI SPA (IT) | 1995-08-23 | — | — | EP | claimed |
| WO-1994010127-A1 | TARTRONIC ACIDS, THEIR ACETALIC ETHERS AND O-ESTERS | DOMPE' FARMACEUTICI S.P.A. (IT) | 1994-05-11 | — | — | WO | claimed |
| EP-0414078-A2 | Disubstituted (quinolin-2-yl-methoxy)-phenylacetic acid derivatives | BAYER AG (DE) | 1991-02-27 | — | — | EP | claimed |
| EP-0344519-A1 | Substituted 4-(quinolin-2-yl-methoxy)phenyl-acetic-acid derivatives | BAYER AG (DE) | 1989-12-06 | — | — | EP | claimed |
| EP-0339416-A1 | Optionally alpha-substituted 4-(quinolin-2-yl-methoxy)phenyl acetic acids and esters | BAYER AG (DE) | 1989-11-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123232-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | CYSLTR1 279/4885CYSLTR2 325/4885GPBAR1 392/4885 |
| US-20020019534-A1 | Gem substituted hydroxamic acids | MMP14, TOP2A, ADAMTS1 | CYSLTR1 2316/4885CYSLTR2 2021/4885GPBAR1 1078/4885 |
| US-20120077847-A1 | ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS | LIPG, LIPA, LIPE | CYSLTR1 1559/4885CYSLTR2 1469/4885GPBAR1 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.